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Rectal cancer patients can be treated conservatively
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Introduction. The strategy of undertaking a watch-and-wait policy without surgical treatment is currently being 
debated in those patients where complete clinical response/regression (cCR) has been diagnosed after preoperative 
irradiation. Its proponents maintain that there is sufficient evidence of efficacy allowing routine use. This means that 
following preoperative chemoradiotherapy, each patient should be investigated for cCR. If so diagnosed, physicians 
are then obliged to give the patient the choice of two treatment options: surgical treatment or watch-and-wait without 
surgery. Radical surgical treatment is adopted as a rescue/salvage therapy if during the watch-and-wait period, local 
recurrence in patients occurs. In contrast, opponents of the strategy of watch-and-wait, purport that evidence for its 
efficacy is inadequate to justify routine use.
Results. Literature data indicates that the rate of cCR depends on the tumour size, with incidence ranging between 
5% and 78% of those patients irradiated prior to surgery. If the patients were kept under watch-and-wait without 
surgery, then the local recurrence rate was around 30%. Such high rates of local recurrences does not however 
disqualify this approach because the efficacy of rescue surgery was high. Distant metastases were rare, up 10% of 
patients, and survivals were even better compared to control patient groups who had been operated on due to not 
achieving cCR; this difference arising from the inherently less aggressive tumours that are sensitive to irradiation. 
Conclusions. The data hitherto indicate that a policy of watch-and-wait may be adopted in patients with CCR after 
chemoradiotherapy. Nevertheless, introducing this strategy requires acquiring experience for diagnosing CCR and 
an efficient organisation and supervision of treatment along with the rigorous follow-up. 
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Introduction
Adopting a watch-and-wait policy in patients diagnosed 
with complete clinical response (cCR) following preoperative 
irradiation, is the most ‘hot topic’ being currently debated 
in rectal cancer; taking place both in the literature [1, 2] 
and at scientific conferences. The essence of this debate 
can be succinctly summarised as follows: Those advocating 
watch-and-wait for cCR patients uphold that evidence for its 
efficacy is sufficient for adopting it to routine treatment [1]. 
In concrete terms, they argue that anyone with pre-op-
erative chemoradiotherapy should be screened for cCR. 
Whenever diagnosed, the physician is obliged to present 
the patient with two possible options: surgical treatment 
such as previously planned, or a watch-and-wait approach 
without surgery. Radical surgical treatment is then used 
during follow-up only as a rescue procedure in patients with 
local recurrence. Proponents of watch-and-wait emphasise 
the advantages of this approach; where the anus and whole 
rectum are preserved. This provides better anorectal and 
sexual functions compared to surgery, and thus a better 
quality of life. In addition, there is no mortality and other 
postoperative complications. Contrastingly, the opponents 
of a watch-and-wait policy argue that there is insufficient 
evidence for the effectiveness of this method in the literature 
for routine use [2]. They argue that this issue still requires 
further research before it can be used in routine practice. 
This viewpoint is shared by most physicians, as reflected in 
all the known official guidelines.
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In preoperative radiotherapy, the watch-and-wait policy 
gives rise to a paradox. On the one hand, radiotherapy is 
discontinued in patients with small cancers for two reasons: 
1) After using modern-day surgery, i.e. total mesorectal exci-
sion, rates of local recurrence are very low, and 2) Radiation 
therapy results in complications, which is most commonly 
an increase in the anterior resection syndrome, i.e. anorectal 
dysfunctions. On the other hand, proponents of watch-
and-wait maintain that indications for patient irradiation 
with small cancers should be widened, as these patients 
are more likely to develop cCR than in advanced cancer 
cases. This allows organ preservation if cCR is achieved after 
chemoradiotherapy, which thereby provides better ano-
rectal function compared to surgically treated patients [3].
Despite many studies, prior to treatment, no test has yet 
been developed that could predict a pathological complete 
response (pCRc) with sufficient accuracy. It is therefore not 
possible to decide before treatment whether only chemo-
radiotherapy is sufficient, or whether resection becomes 
necessary.
Biological backgrounds  
for a watch-and-wait policy
Relationship between radiationsensitivity  
and aggressiveness of rectal cancer
Rectal cancer is a heterogeneous disease. About 15% 
of all cancer are radiosensitive, which after preoperative 
chemoradiotherapy and resection causes that no cancer is 
found by the pathologist in postoperative specimen, either 
in the bowel or regional lymph nodes. In patients attaining 
pCR, prognosis is significantly better than in those without 
pCR. For example, Mass et al. found 16% of pCR patients from 
all preoperative chemoradiotherapy in a multiple centres 
study [4]. At fFive years local recurrence was observed in 
3% of patients and distant metastases in 9%, whilst in those 
with persisting cancer after chemoradiotherapy such rates 
were respectively10% and 23%. 
Five-year cancer-free survival was 83% in pCR patients 
and 66% in patients with persistent cancer; p < 0.001. This 
indicates that radiosensitive cancer is less aggressive than 
radioresistant cancer. This is not only reflected in lowered 
local recurrence rates, but also by a reduced susceptibility 
to distant metastases [4].
Efficacy of rescue surgery
Local recurrences after cCR are common, being about 
one third of patients [5–8]. This is opposed to around 5% 
relapses occurring after surgery. For this reason, an integral 
part of the watch-and-wait policy is rescue surgery in the 
event of local recurrence. A condition for adopting this ap-
proach, as a valuable treatment, is the high efficacy of rescue 
surgery. Indeed, hitherto published long-term outcomes 
after rescue surgery do not appear any worse than those 
for patients operated on directly after chemoradiotherapy 
when having the same stages of cancer [5, 6]. It should 
however be stressed that that these studies were often 
performed on a limited number of patients, and observa-
tions were frequently short-term. 
The most numerous study by Habr-Gama et al. [5], 
include only 28 patients with local recurrences occurring 
during observation in cCR patients after receiving chemo-
radiotherapy. In 5 of these (18%), distant metastases were 
observed in further follow-up. Rescue surgery was per-
formed in 26 patients, 4 of whom had local recurrence. Thus, 
79% of patients with locally advanced disease were finally 
cured of the primary tumour. 
Likewise, favourable outcomes have been reported in 
other studies on less numerous patient groups and with 
shorter follow-ups [6–9]. These showed significantly better 
efficacy than those obtained after treatment of local recur-
rence after radical surgery. In such patients, effective radical 
resection of the recurrence is rarely possible due to involve-
ment of other organs and/or the coexistence of distant 
metastases. If the resection succeeds, long-term outcomes 
are however unfavourable. Because of the substantially 
different outcomes after the treating these two types of 
recurrence, one study group has proposed that this term 
be reserved only for local recurrence after radical surgical 
treatment, whereas local recurrence occurring in patients 
during watch-and-wait should be termed ‘regrowth’ [1].
For the same reason, another study did not consider re-
growth when undergoing radical rescue surgery as a failure 
of treatment [7]. Treatment failure was recognised only when 
there was recurrent local re-regrowth after rescue surgery 
or when distant metastases were diagnosed.
Correlation between cCR and pCR
cCR does not always mean that there are no residual, 
residual subclinical disease in the bowel wall or lymph nodes 
of the mesorectum. This has been shown by pathological 
studies on patients that underwent resection despite achiev-
ing cCR. In around 30% of these cases, cancer cells were found 
in the bowel wall [10, 11]. As mentioned previously, in a similar 
number of cases, regrowths were seen in the bowel wall if 
patients had been under observation without surgery [5–8]. 
In addition, in all operated patients with bowel wall cPR, 5% 
were observed to have mesorectal lymph node metastases. 
Indeed, in those patients observed after cCR, there were only 
a few cases of recurrence found in the mesorectal nodes [6]. 
Nevertheless, this kind of regrow occurs rarely; recurrence in 
the bowel wall is much more frequent.
Likewise, when pCR is recognised this does not neces-
sarily mean that so is cCR. In a significant proportion of pCR 
cases, there is a persistent tumour or ulcer present [10–14]. 
Only microscopic examination shows that the tumour is not 
malignant, but is only composed of stromal fibrous tissue.
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Table I presents outcomes of prospective studies evalu-
ating clinical and pathological rates of complete responses 
to preoperative chemoradiotherapy in relation to tumour 
size [10, 11, 13, 14]. The smaller the tumour, the more often is 
pCR achieved after chemoradiotherapy and the more often 
does it coincide with cCR [10–12]. Preoperative radiotherapy 
in patients with advanced cancer results in about 15% of 
pCR [4, 6, 14]. However, cCR occurs less frequently in around 
5% of patients [15].
In most patients with a large tumour prior to treatment 
and in whom pCR was achieved, there was however no cCR 
as the remaining tumour consisting of solely fibrous tissue 
imitating persistent cancer [13–15]. In patients with up to 
a 3 cm diameter cancer, cCR and pCR rates increase to about 
45% [10, 11] and around 2/3rds of patients achieving cCR are 
also diagnosed with pCR; in the remaining 1/3rd , despite 
cCR, microscopic disease is observed upon histopathologi-
cal examination (clinical assessment being false positive). 
Table I shows that there are two main criteria determin-
ing the best candidates for undergoing watch-and-wait, 
namely those with a small size cancer but not those with 
large tumours; pCR being more often achieved which more 
frequently correlates with cCR.
Besides the studies presented in Table I, others confirm 
the above conclusions. A study by Das et al. [16] on 108 
patients achieving pCR after chemoradiotherapy demon-
strated a pCR rate of 23% in those with tumours involv-
ing less than 60% of the bowel circumference, compared 
to 13% in tumour occupied more than 60% of the bowel 
circumference. 
Multivariate analysis has showed that the extent to 
which the bowel circumference is involved constitutes the 
only factor associated with pCR. Van Stiphout et al. [17], 
studied 953 patients, and demonstrated that the length of 
the intestinal wall involved, significantly correlated with the 
pCR rates. The included nomogram shows that the pCR rate 
clearly increases when the tumour is less than 5 cm in size.
PCR and cCR rates are not dependent on whether clini-
cally diagnosed metastases to regional lymph nodes are 
present. Complete regression at the primary tumour was 
achieved in a similar proportion of patients without clinically 
diagnosed nodal metastases, like in patients with metasta-
ses [6, 9, 18]. Furthermore, there was a strong correlation 
between the radiosensitiveness of the primary tumour with 
the radiosensitiveness of the metastases to lymph nodes. 
Thus, if a complete regression of the primary tumour was 
achieved, it was most commonly accompanied by complete 
regression of nodal metastases. As aforementioned, the 
proportion of patients with ypT0N+ disease was only 5% 
of all patients with ypT0 [4].
Long-term results in cCR patients  
undergoing watch-and-wait
Table II presents prospective and retrospective study 
outcomes evaluating efficacy when surgical intervention 
is withheld if cCR is achieved 6–10 weeks after chemora-
diotherapy. This data was retrieved following a systematic 
review of the literature. Outcomes of most studies are en-
couraging. A watch-and-wait policy was only tested in two 
randomised trials [15, 19]; design of one of these studies hav-
ing been methodologically optimal [15]. Patients achieving 
cCR after chemoradiotherapy were randomly selected for 
watch-and-wait or total mesorectal excision. Only 6 patients 
(5%) out of 160 achieved cCR over two years of recruitment; 
two were randomized for resection (the pathological study 
revealed ypT0N0 and ypT2N0) and four for watch-and-wait 
(one was found to have regrowth whilst the other three 
had sustained cCR).
For the second randomised study, patients were qualified 
(n = 88) with a low-lying tumour with cT2 or cT3 disease, in-
volving no more than 2/3rds of the bowel circumference [19]. 
Both arms of this study used preoperative radiotherapy; 
in one, a dose of 39 Gy in 17 fractions was given, whilst 
in the second the dose was increased with ortovoltage 
irradiation and in patients achieving complete regression, 
brachytherapy was also given. In the study arm, using the 
increased irradiation dose, 6 patients (14%) achieved cCR. 
These patients underwent watch-and-wait without surgery; 
none of them had any local recurrence during a long follow-
up period. In both randomised groups, the proportions of 
Table I. Clinical and pathological complete cancer response to preoperative chemoradiotherapy according to tumour progression
Tumour size / Study author Number of 
patients
cCR (%) pCR (%) cCR patients (%)  
not achieving pCRPR
pCRCPR patients (%)  
not achieving cCR
Small tumours up to 3 cm,  
mainly T2 
Garcia-Anguilar [10] 77 56% 44% 33% 15%
Bujko [11] 89 34% 44% 38% 33%
Advanced tumours T3–4
Grillem [13] 94 3% 15% 0% 86%
Smith F [14] 220 6% 14% 8% 62% 
cCR — clinical complete regression; pCRCPR — pathological complete regression
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local recurrences, overall survival and disease-free survival 
were similar.
All other studies were observational. The pioneer for 
propounding the watch-and-wait policy is Habr-Gama’s 
team from Brazil [5, 18, 20–22]. In those patients where 
achieving cCR is uncertain, then a full-thickness local exci-
sion of the tumour is performed. It is noteworthy that the 
primary tumour in patients treated by this team was not 
large, where the mean tumour size in one study was 3.7 cm 
and in many patients did not penetrate outside of the bowel 
wall (cT2) [5]. In one study, cCR was achieved in 49% of 
patients [5] in whom local recurrence was observed in 31% 
of cases. Outcomes of rescue surgery in these patients are 
described above. In the whole group of patients achieving 
cCR, cancer specific survival was 94% after 5 years.
Renehan et al. [7] reported the routine use of watch-and-
wait in 12% of patients who achieved cCR after routine pre-
operative chemoradiotherapy for consecutive patients from 
three UK centres. Although local recurrence was in 34% of 
patients, the overall survival after 3 years was 96% compared 
with 87% in control group that underwent surgery after 
chemoradiotherapy; p = 0.024. It should be deemed that the 
inferior survival in the group of surgical patients arose from 
biologically inherent lower aggressiveness of radiosensitive 
cancers; this issue is presented in the text above.
In a prospective study on 51 patients, Appelt et al. [8] 
showed that unlike most published reports, where routine 
preoperative chemoradiotherapy was used with 45–50 Gy, 
the dose here was increased to 60 Gy with external beams. 
In addition, 5 Gy was administered to one brachytherapy 
fraction by an applicator placed in the rectum; the propor-
tion achieving cCR being as high as 78%. These patients 
underwent watch-and-wait without surgery. The risk of 
local recurrence after one year was 16%. All reports indicate 
that distant metastases in cCR patients are rare, being at 
a maximum of 10% patients. Outcomes from other studies 
are presented in Table II [23–27]. In several of these, the deci-
sion not to treat metastases in regional lymph nodes (cN+) 
was not a contraindication for watch-and-wait [6, 9, 18]. 
It has not been shown that treatment outcomes in this 
subgroup were any worse than patients diagnosed as cN0 
before treatment. 
At our centre a prospective study was conducted on pa-
tients aged over 70 years with tumours of up to 5 cm involv-
ing no more than 60% of the bowel wall circumference [28]. 
The main justification for this study was in the chances 
for improving survival in patients achieving cCR resulting 
from the avoidance of postoperative mortality [29]. Postop-
erative mortality after total mesorectal excision in patients 
older than 75 years was high, and was 16% after 6 months 
compared to 4% in younger patients [30]. Of the first 35 
study patients, cCR was achieved in 31% of cases [29]. cCR 
was observed not only after chemoradiotherapy but also 
in 4 out of 14 patients (29%) irradiated with 5 × 5 Gy and 
Table II. Prospective studies in patients with clinical complete cancer regression (cCR) after chemoradiotherapy undergoing observation without surgery
Study author Number of patients 
treated by irradiation 
cCR rate (%) in patients 
without surgery 
Local recurrence rates (%) in cCR patients,  
median follow-up 
Habr-Gama Team
Habr-Gama [23] 173 33% 11% in patients achieving cCR after 12 months 65 months. 
Habr-Gama [21] 361 34%, including ypT0 patients 
after local excision 
24% (19% during first year & 5% later), 60 months 
Habr-Gama [22] 29 48% 21%, 23 months
Habr-Gama [5] 183 49% 31%, 60 months
Other authors
Martens [6] Numbers unknown 100 patients 15%, 41 months
Appelt [8] 51 78% 16% after 1 year observation
Renehan [7] 259 12% + 98 registered patients 34%, 33 months
Dalton [23] 49 24% 50%, 25 months 
Nahas [15] 118 5% 1 amongst 4 
Araujo [27] Numbers unknown 42 28%, 48 months
Yu [26] Numbers unknown 19 cCR patients and small 
residual tumour 
47%, observation — no data
Rupinski [28] 35 31% Observation too short for assessment 
Nakagawa [25] 52 19% 80% 
Smith [9] 297 Unknown, 11% cCR observed 19%, 23 months
Hughes [24] 266 Unknown, 4% cCR observed 60%, 46 months
Ortholan [19] 42 14% 0%, 132 months
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then evaluated after about 10 weeks. A 5 × 5 Gy treatment 
was administered to patients unfit for chemotherapy. CCR 
patients were observed. In addition, 34% of the patients 
underwent local resection of the residual tumour. Thus in 
total, organ preservation was achieved in 66% of patients. 
The too short observations made it impossible to evaluate 
long-term outcomes.
The Table II data show large differences both in the 
achieved cCR rates and local recurrence rates in patients 
without surgery. This could have been caused by select-
ing patients with very advanced cancer as candidates for 
conservative treatment or through using a wide definition 
of cCR. For example, Yu et al. [26] and Hughes et al. [24] re-
ported high rates of local recurrence, which did not include 
endoscopic evaluation and was based solely on MR or on 
digital rectal examinations.
Definition of CCR
Recently, Habr-Gama et al. [31] have defined cCR in de-
tail. According to her, cCR should only be diagnosed if there 
are no mucosal lesions or if a smooth scar with or without 
telangiectasia is visible; mucosal stiffening is possible at this 
location. Any ulcer, even superficial ones, palpable lumps 
or mucosal irregularities and bowel lumen narrowing are 
treated as being non-cCR. Retrospective photographic im-
age analyses of postoperative material showed that if this 
definition was used, only 10% of patients with a pathologi-
cal diagnosis of complete regression coincidences with the 
clinical diagnosis of complete regression [14].
It should be stressed that none of the imaging investiga-
tions such as CT, MRI or PET are enough accurate that they 
can be used to determine whether pCR was also achieved 
in cCR patients [32–34]. In the latter, pelvic MRI is rather an 
auxiliary aid, since diagnosing residual lesions does not 
exclude the diagnosis of complete regression [31]. This is-
sueis described in detail by Lambregts et al. [32]. MRI serves 
rather as a baseline investigation, possibly needed for later 
comparisons during subsequent follow-up. Similarly, his-
topathological examination of scar or persisting lesions 
biopsies after radiotherapy is not reliable because of the 
high rate of false-negatives [28, 35, 36]. Residual cancer is dif-
ficult to detect, as single cancer cells survived in the deeper 
layers of the submucosal or in muscularis propia [37, 38].
Conclusions
Hitherto, data indicates that a watch-and-wait strategy 
may be used in patients achieving cCR after chemoradio-
therapy. Introducing this approach nevertheless requires 
that experience in diagnosing cCR be acquired, along with 
efficient organisation and supervision over treatment and 
follow-up.
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